Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1103/physreve.50.1144 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and myocardial infarction undergoing percutaneous coronary intervention: A systematic review and meta-analysis.
Am J Prev Cardiol
March 2025
Ahmanson-UCLA Cardiomyopathy Center, Division of Cardiology, University of California Los Angeles, Los Angeles, CA, USA.
Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have shown benefits in improving cardiovascular (CV) outcomes in patients with heart failure (HF) and may mitigate symptom progression in myocardial infarction (MI). However, their effectiveness in patients with type 2 diabetes and MI undergoing percutaneous coronary intervention (PCI) is unclear.
Methods: To identify eligible studies, a comprehensive search of electronic databases, PubMed, Cochrane Library, Scopus and Embase, was conducted from inception until May 2024.
Cardio-renal effect of dapagliflozin and dapagliflozin- saxagliptin combination on CD34 + ve hematopoietic stem cells (HSCs) and podocyte specific markers in type 2 diabetes (T2DM) subjects: a randomized trial.
Stem Cell Res Ther
January 2025
Department of Medicine, Veterans Affairs Medical Center, Washington, DC, USA.
Introduction: Effects of Dapagliflozin (Dapa) and Dapagliflozin-Saxagliptin combination (Combo) was examined on peripheral blood derived CD34 + Hematopoetic Stem Cells (HSCs) as a cellular CVD biomarker. Both Dapa (a sodium-glucose co-transporter 2 or SGLT2, receptor inhibitor) and Saxagliptin (a Di-peptydl-peptidase-4 or DPP4 enzyme inhibitor) are commonly used type 2 diabetes mellitus or T2DM medications, however the benefit of using the combination has not been evaluated for cardio-renal risk assessment, in a real-life practice setting, compared to a placebo.
Hypothesis: We hypothesized that Dapa will improve the outcomes when compared to placebo and the Combo maybe even more beneficial.
Thoracolumbar spine muscle size and composition changes in long-duration space missions.
Life Sci Space Res (Amst)
February 2025
Department of Biomedical Engineering, Center for Injury Biomechanics, Wake Forest University School of Medicine. 575 N. Patterson Avenue, Suite 530. Winston-Salem, NC 27101, USA. Electronic address:
Muscle atrophy occurs with extended exposure to microgravity. This study quantified the overall muscle size, lean muscle area and fat infiltration changes pre- to post-flight that occur in the thoracic and lumbar spine with long-duration spaceflight. Pre- and post-flight magnetic resonance imaging (MRI) scans were obtained from 9 crewmembers on long-duration (≥6 months) International Space Station (ISS) missions.
View Article and Find Full Text PDFLattice coherency engineering trigger rapid charge transport at the heterointerface of Te/InO@MXene photocatalysts for boosting photocatalytic hydrogen evolution.
J Colloid Interface Sci
January 2025
College of Chemistry and Chemical Engineering, Qiqihar University, Qiqihar 161006, PR China; Heilongjiang Provincial Key Laboratory of Catalytic Synthesis for Fine Chemicals, Qiqihar University, Qiqihar 161006, PR China. Electronic address:
The establishment of heterojunctions has been demonstrated as an effective method to improve the efficiency of photocatalytic hydrogen production. Conventional heterojunctions usually have random orientation relationships, and heterointerfaces can hinder photogenerated carrier transport due to larger lattice mismatches, thus reducing the photoelectric conversion efficiency. In this study, a novel Te/InO@MXene lattice coherency heterojunction was prepared by leveraging the identical lattice spacing of InO (222) and Te (021) crystal face.
View Article and Find Full Text PDFEffect of Staggered vs. Simultaneous Co-Administration of Bempedoic Acid on Pharmacokinetics of Pravastatin: Randomized, Cross-Over Clinical Trial in Healthy Volunteers.
Pharmaceutics
January 2025
Medical Faculty Heidelberg, Heidelberg University, 69117 Heidelberg, Germany.
: Bempedoic acid (BA) is a novel cholesterol-lowering agent with proven positive effects on cardiovascular endpoints. Because it is an inhibitor of the hepatic transporters OATP1B1 and OATP1B3, two uptake transporters regulating the intrahepatic availability of statins, it increases the systemic exposure of co-administered statins. This interaction could raise the risk of myopathy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!